First Real-World Data on Weekly Growth Hormone Shows Conservative Dosing Patterns
German registry reveals physicians start most patients on lower-than-recommended doses of new long-acting growth hormone therapies.
Summary
The INSIGHTS-GHT registry tracked the first 100 patients receiving new weekly growth hormone injections in Germany. These long-acting formulations reduce injection frequency from daily to weekly for growth hormone deficiency. The study found 82% of pediatric patients and 41% of adult patients received starting doses below manufacturer recommendations, with median doses at 92% of recommended levels. Most pediatric patients were male with idiopathic growth hormone deficiency, while adult patients predominantly had organic causes. The conservative dosing approach likely reflects physician caution with new therapies and individualized patient management in real-world practice.
Detailed Summary
Growth hormone deficiency affects thousands of patients who traditionally require daily injections, creating adherence challenges that can compromise treatment outcomes. Three new long-acting growth hormone (LAGH) formulations now allow weekly dosing: lonapegsomatropin, somapacitan, and somatrogon, each using different mechanisms to extend hormone activity.
The INSIGHTS-GHT registry, Germany's first cross-product growth hormone database, tracked real-world usage patterns in the first 100 patients receiving these weekly therapies. The study included 70 pediatric patients from 15 centers and 31 adult patients from 6 centers, providing unprecedented insight into how physicians actually prescribe these new therapies outside clinical trials.
Key findings revealed conservative prescribing patterns: 82% of pediatric patients received starting doses below manufacturer recommendations, with a median of 92% of the suggested dose. Adult patients showed similar patterns, with 41% receiving lower-than-recommended starting doses. Most pediatric patients (76%) were male with idiopathic growth hormone deficiency, while 84% of adults had organic causes. Notably, 54% of pediatric patients switched from daily therapy, while all adult patients were switchers.
The conservative dosing likely reflects physician caution with new therapies, desire to minimize side effects, and individualized patient management. Only two mild adverse events were reported (headache and nosebleed), suggesting good early tolerability. These real-world patterns differ from clinical trial protocols, highlighting the importance of registry data for understanding actual clinical practice.
This early evidence suggests physicians are successfully integrating weekly growth hormone therapy into practice while taking measured approaches to dosing. Continued follow-up will be crucial to assess whether conservative initial dosing affects long-term growth outcomes and whether dose adjustments optimize treatment effectiveness.
Key Findings
- 82% of pediatric patients received LAGH starting doses below manufacturer recommendations
- Weekly growth hormone therapy showed good early tolerability with only 2 mild adverse events
- 54% of pediatric patients switched from daily therapy, while all adult patients were switchers
- Conservative dosing patterns suggest physician caution with new long-acting formulations
- Real-world prescribing differs significantly from clinical trial protocols
Methodology
Observational registry study tracking 101 patients (70 pediatric, 31 adult) from 21 German endocrinology centers receiving any of three long-acting growth hormone products. Data collected through electronic capture system with quality checks and onsite monitoring.
Study Limitations
Early interim analysis with limited follow-up time to assess long-term efficacy and safety. IGF-I measurements varied across institutions using different assays, limiting standardized comparisons. Small sample size may not represent broader prescribing patterns.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.